Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.17  

 
 

AMENDMENT TO LOAN AGREEMENT AND NOTE    
  

        This amendment (the "Amendment"), dated as of the date specified below, is by and between the borrower (the
"Borrower") and the bank (the "Bank") identified below. 

 
 

RECITALS    
  

        A.    The
Borrower and the Bank have executed a Loan Agreement (the "Agreement") dated JANUARY 29, 2001 and the Borrower has
executed a Note (the "Note"), dated JANUARY 29, 2001, either or both which may have been amended from time to time, and the Borrower (and if applicable,
certain third parties) have executed the collateral documents which may or may not be identified in the Agreement and certain other related documents (collectively the "Loan
Documents"), setting forth the terms and conditions upon which the Borrower may obtain loans from the Bank from time to time in the original amount of $5,000,000.00, as may be
amended from time to time. 

        B.    The
Borrower has requested that the Bank permit certain modifications to the Agreement and Note as described below. 

        C.    The
Bank has agreed to such modifications, but only upon the terms and conditions outlined in this Amendment. 

 
 

TERMS OF AGREEMENT    
  

        In consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Borrower and the Bank agree as follows: 

        /x/    Extension of Maturity Dates.    If checked here, any references in the Agreement or Note to the
maturity date or date of final payment are hereby deleted and replaced with "MARCH 31, 2002". 

        / /    Change in Maximum Loan Amount.    If checked here, all references to "$N/A" in the Agreement and in
the Note (whether or not numerically) as the maximum loan amount which may be borrowed from time to time are hereby deleted and replaced with "$N/A". 

        / /    Change in Multiple Advance Termination Date.    If checked here, all references to "N/A" as the
termination date for multiple advances are hereby deleted and replaced with "N/A". 

 Change in Financial Covenant(s).  

          (i)  / /    If
checked here, all references to "$                        " in the Agreement as the minimum Net Working Capital amount
are hereby deleted and replaced with "$                        " for the period beginning
                         and thereafter.
 

        (ii)  / /    If
checked here, all references to "$                        " in the Agreement as the minimum Tangible Net Worth amount
are hereby deleted and replaced with "$                        " for the period beginning
                         and thereafter. 

        (iii)  / /    If
checked here, all references to "                        " in the Agreement as the maximum Debt to Worth Ratio are
hereby deleted and replaced with "                        " for the period beginning
                         and thereafter. 

        (iv)  / /    If
checked here, all references to "                        " in the Agreement as the minimum Current Ratio are hereby
deleted and replaced with "                        " for the period beginning
                         and thereafter.
 

        (v)  / /    If
checked here, all references to "$                        " in the Agreement as the maximum Capital Expenditures amount
are hereby deleted and replaced with "$                        " for the period beginning
                         and thereafter. 

        (vi)  / /    If
checked here, all references to "                        " in the Agreement as the minimum Cash Flow Coverage Ratio
are hereby deleted and replaced with "                        " for the period beginning
                         and thereafter. 

      (vii)  / /    If
checked here, all references to "$                        " in the Agreement as the maximum Officers, Directors,
Partners, and Management Salaries and Other Compensation amount are hereby deleted and replaced with
"$                        " for the period beginning
                         and thereafter. 

        / /    Change in Payment Schedule.    If checked here, effective upon the date of this Amendment, any
payment terms are amended as follows: 

        /x/    Change in Interest Rate.    If checked here, effective upon the date of this Amendment, interest
payable under the Note is amended as follows: 

The
unpaid principal balance will bear interest at an annual rate described in the Interest Rate Rider attached to this Amendment. 

        / /    Change in Late Payment Fee.    If checked here, subject to applicable law, if any payment is not made
on or before its due date, the Bank may collect a delinquency charge of                         % of the unpaid amount.
Collection of the late payment fee shall not be deemed to be
a waiver of the Bank's right to declare a default hereunder. 

        Effectiveness of Prior Documents.    Except as specifically amended hereby, the Agreement, the Note and the other Loan Documents
shall remain in full force and effect in accordance with their respective terms. All warranties and representations contained in the Agreement and the other Loan Documents are hereby reconfirmed as of
the date hereof. All collateral previously provided to secure the Agreement and/or Note continues as security, and all guaranties guaranteeing obligations under the Loan Documents remain in full force
and effect. This is an amendment, not a novation. 

        Preconditions to Effectiveness.    This Amendment shall only become effective upon execution by the Borrower and the Bank, and
approval by any other third party required by the Bank. 

        No Waiver of Defaults; Warranties.    This Amendment shall not be construed as or be deemed to be a waiver by the Bank of
existing defaults by the Borrower, whether known or undiscovered. All agreements, representations and warranties made herein shall survive the execution of this Amendment. 

        Counterparts.    This Amendment may be signed in any number of counterparts, each of which shall be considered an original, but
when taken together shall constitute one document. 

        Authorization.    The Borrower represents and warrants that the execution, delivery and performance of this Amendment and the
documents referenced herein are within the authority of the Borrower and have been duly authorized by all necessary action. 

        Attachments.    All documents attached hereto, including any appendices, schedules, riders, and exhibits
to this Amendment, are hereby expressly incorporated herein by reference.

Dated
as of: JANUARY 25, 2002. 

	

 	

 	

 	
 	
PHOENIX GOLD INTERNATIONAL, INC.

	(Individual Borrower)	 	Borrower Name (Organization)
	

 	

 	

(SEAL)	
 	

a	

OREGON Corporation
	
	 	 	 	

	

Borrower Name	

N/A
	
 	

By:	

/s/  JOSEPH K. O'BRIEN, CFO      

	 	 	 	 	Name and Title:	AUTHORIZED OFFICER, TITLE

	

 	

 	

(SEAL)	
 	

By:	

 	

 
	
	 	 	 	

	

Borrower Name	

N/A	
 	

Name and Title:	

 
	 	
	 	 	 	

	

Agreed to:	
 	

 
	

U.S. BANK N.A.
	
 	

 
	

By:	

/s/  DAVID WYNDE      
	
 	

 
	Name and Title:	DAVID WYNDE

VICE PRESIDENT
	 	 

 
 

INTEREST RATE RIDER    
  

        This Rider is made part of the Amendment to Loan Agreement and Note (the "Amendment") dated JANUARY 25,
2002 by the undersigned borrower (the "Borrower") in favor of U.S. BANK, N.A. (the "Bank") as of the
date identified below. The following interest rate description is hereby added to the Amendment: 

        Interest Rate Options.    Interest on each advance hereunder shall accrue at one of the following per annum rates selected by
Borrower ("n/a" indicates rate option is not available, but Prime Rate Loan option must always be selected) (i) upon notice to the Bank, 0.000%
plus the prime rate announced by the Bank from time to time, as and when such rate changes (a "Prime Rate Loan"); (ii) upon a minimum of two New York banking days prior notice, 1.750% plus the
1,2,3, month LIBOR rate quoted by the Bank from Telerate Page 3750 or any successor thereto (which shall be the LIBOR rate in effect two New York banking days prior to commencement of the LIBOR
loan advance) (a "LIBOR Rate Loan"); or (iii) upon notice to the Bank, n/a% plus the rate, determined solely by the Bank, at which the Bank would be able to borrow funds of comparable amounts
in the Money Markets for a 1, 3, month period, including FDIC insurance, reserve requirements and other explicit or implicit costs levied by any regulatory agency (a "Money Market Rate Loan"). The
term "Money Markets" refers to one or more wholesale funding markets available to the Bank, including negotiable certificates of deposit, commercial paper, eurodollar deposits, bank notes, federal
funds and others. If a LIBOR Rate Loan or Money Market Rate Loan is prepaid, whether by the Borrower, as a result of acceleration upon default or otherwise, the Borrower agrees to pay all of the
Bank's costs, expenses and Interest Differential (as determined by the Bank) incurred as a result of such prepayment. The term "Interest Differential" shall mean that sum equal to the greater of 0 or
the financial loss incurred by the Bank resulting from prepayment, calculated as the difference between the amount of interest the Bank would have earned (from like investments in the Money Markets as
of the first day of the LIBOR or Money Market Rate Loan) had prepayment not occurred and the interest the Bank will actually earn (from like investments in the Money Markets as of the date of
prepayment) as a result of the redeployment of funds from the prepayment. Because of the short-term nature of this facility, the Borrower agrees that the Interest Differential shall not be discounted
to its present value. Any prepayment of a LIBOR Rate Loan or Money Market Rate Loan shall be in an amount equal to the remaining entire principal balance of such loan. In the event the Borrower does
not timely select another interest rate option at least two banking days before a LIBOR Rate Loan or Money Market Rate Loan expires, the Bank may at any time thereafter convert the LIBOR Rate Loan or
Money Market Rate Loan to a Prime Rate Loan, but until such conversion, the funds advanced under the expired LIBOR Rate Loan or Money Market Rate Loan shall continue to accrue interest at the same
rate as
the interest rate under such expired LIBOR Rate Loan or Money Market Rate Loan, as applicable. The Bank's internal records of applicable interest rates shall be determinative in the absence of
manifest error. Each LIBOR or Money Market rate option selected shall apply to a minimum principal amount of $100,000. For determining payment dates for LIBOR Rate Loans, the New York banking day
shall be the standard convention. In the event after the date of initial funding any governmental authority subjects Bank to any new or additional charge, fee, withholding or tax of any kind with
respect to any loans hereunder or changes the method of taxation of such loans or changes the reserve or deposit requirements applicable to such loans, the Borrower shall pay to the Bank such
additional amounts as will compensate the Bank for such costs or lost income resulting therefrom as reasonably determined by the Bank. 

Dated
as of: JANUARY 25, 2002 

	

 	

 	

 	
 	
PHOENIX GOLD INTERNATIONAL, INC.

	(Individual Borrower)	 	Borrower Name (Organization)
	

 	

 	

(SEAL)	
 	

a	

OREGON Corporation
	
	 	 	 	

	

Borrower Name	

N/A
	
 	

By	

/s/  JOSEPH K. O'BRIEN, CFO      

	 	 	 	 	Name and Title:	AUTHORIZED OFFICER, TITLE

	

 	

 	

(SEAL)	
 	

By	

 	

 
	
	 	 	 	

	

Borrower Name	

N/A	
 	

Name and Title	

 
	 	
	 	 	 	

QuickLinks

AMENDMENT TO LOAN AGREEMENT AND NOTE

RECITALS

TERMS OF AGREEMENT

INTEREST RATE RIDER<Page>

                                                                    Exhibit 10.1

                              EMPLOYMENT AGREEMENT

         THIS EMPLOYMENT AGREEMENT (the "Agreement") is made and entered into
effective as of November 16, 2001, by and between Maxim Pharmaceuticals, Inc.,
(the "Company"), and Kurt R. Gehlsen, Ph.D. ("Executive"). The Company and
Executive are hereinafter collectively referred to as the "Parties," and
individually referred to as a "Party."

                                    RECITALS

         A.       The Company desires assurance of the association and services
of Executive in order to retain Executive's experience, skills, abilities,
background and knowledge, and is willing to engage Executive's services on the
terms and conditions set forth in this Agreement.

         B.       Executive desires to be in the employ of the Company, and is
willing to accept such employment on the terms and conditions set forth in this
Agreement.

                                    AGREEMENT

         In consideration of the foregoing recitals and the mutual promises and
covenants herein contained, and for other good and valuable consideration, the
Parties, intending to be legally bound, agree as follows:

1.       EMPLOYMENT.

         1.1      The Company hereby employs Executive, and Executive hereby
accepts continued employment by the Company, upon the terms and conditions set
forth in this Agreement, effective as of the date first set forth above
("Commencement Date"). This Agreement shall continue in effect until terminated
pursuant to Section 5 below.

         1.2      Executive shall be the Senior Vice-President, Development and
Chief Technical Officer of the Company (or a position of at least comparable
status) and shall serve in such other capacity or capacities as the Chief
Executive Officer and/or the Company's Board of Directors ("Board") may from
time to time prescribe.

         1.3      Executive shall do and perform all services, acts or things
necessary or advisable to manage and conduct the business of the Company and
which are normally associated with the position of Senior Vice-President,
Development and Chief Technical Officer, consistent with the Bylaws of the
Company, as well as its general employment policies and practices, including,
but not limited to management of the Company's research and development programs
issuing from its technologies, including; primary responsibility for business
development and corporate partnering activities, over-site and administration of
clinical trials, supervision of collaborator and contract laboratory
relationships, planning and supervision of research programs, preparation of
strategic development and marketing plans for the Company's technologies,
evaluation of scientific and other technologies for acquisition, and
participation in financing presentations and otherwise representing the Company
at various meetings. However, at all times during his employment Executive shall
be subject to the direction and policies from time to time established by the
Board and/or the Chief Executive Officer.

         1.4      Unless the Parties otherwise agree in writing, during the term
of this Agreement, Executive shall perform the services he is required to
perform pursuant to this Agreement at the Company's offices, located at 8899
University Center Lane, Suite 400 or at any other place at which the Company
maintains an office; provided, however, that the Company may from time to time
require Executive to travel temporarily to other locations in connection with
the Company's business.

<Page>

2.       LOYAL AND CONSCIENTIOUS PERFORMANCE; NONCOMPETITION

         2.1      During his employment by the Company, Executive shall devote
his full business energies, interest, abilities and productive time to the
proper and efficient performance of his duties under this Agreement.

         2.2      During the term of this Agreement, Executive shall not engage
in competition with the Company, either directly or indirectly, in any manner or
capacity, as adviser, principal, agent, partner, officer, director, employee,
member of any association or otherwise, in any phase of the business of
developing, manufacturing and marketing of products which are in the same field
of use or which otherwise compete with the products or proposed products of the
Company.

         2.3      Ownership by Executive, as a passive investment, of less than
one percent (1%) of the outstanding shares of capital stock of any corporation
with one or more classes of its capital stock listed on a national securities
exchange or publicly traded in the over-the-counter market shall not constitute
a breach of this paragraph.

3.       COMPENSATION OF EXECUTIVE.

         3.1      While employed by the Company, as compensation for proper and
satisfactory performance of all duties to be performed hereunder, the Company
shall pay Executive an annual base salary of Two Hundred Seventy Thousand
Dollars ($270,000) per year (the "Base Salary"), payable in regular periodic
payments in accordance with Company policy. Such salary shall be prorated for
any partial year of employment on the basis of a 365-day fiscal year. In
addition, Executive will be eligible for an incentive bonus of up to 25% of Base
Salary, based upon defined milestones, during the agreement period. In addition,
Executive will receive $75,000 upon approval of the U.S. NDA for Ceplene if such
approval is obtained by November 17, 2002.

         3.2      Executive's compensation may be changed from time to time by
mutual agreement of Executive and the Board.

         3.3      All of Executive's compensation shall be subject to customary
withholding taxes and any other employment taxes as are commonly required to be
collected or withheld by the Company.

         3.4      Executive shall be entitled to vacation and illness days
consistent with the Company's standard practice for its employees generally.

         3.5      Executive shall, at the discretion of the Board, be entitled
to participate in the benefits for which he is eligible under the terms and
conditions of the standard Company benefits which may be in effect from time to
time and provided by the Company.

4.       EXPENSE REIMBURSEMENT.

         4.1      Executive shall be entitled to receive prompt reimbursement of
all reasonable business and travel expenses incurred by Executive in connection
with the business of the Company. Such expenses must be properly accounted for
under the policies and procedures established by the Company.

5.       TERMINATION.

         5.1      The Company may terminate Executive's employment under this
Agreement "for cause" by delivery of written notice to Executive specifying the
cause or causes relied upon for such termination. If Executive's employment
under this Agreement is terminated by the Company for cause under this section,
Executive shall be entitled to receive only accrued Base Salary and other
accrued benefits required by law, prorated to the date of termination. Executive
will not be entitled to severance pay, pay in lieu of notice or any other such
compensation. Grounds for the Company to terminate this Agreement "for cause"
shall be limited to the occurrence of any of the following events:

                  5.1.1    If Executive is in material breach of any provision
of this Agreement;

                                       2
<Page>

                  5.1.2    Executive's engaging or in any manner participating
in any activity which is competitive with or intentionally injurious to the
Company or which violates any provision of Section 7 of this Agreement;

                  5.1.3    Executive's commission of any fraud against the
Company or use or appropriation for his personal use or benefit of any funds or
properties of the Company not authorized by the Board to be so used or
appropriated;

                  5.1.4    Executive's conviction of any crime involving
dishonesty or moral turpitude;

                  5.1.5    Conduct by Executive which in good faith and
reasonable determination of the Board demonstrates gross unfitness to serve.

         Any notice of termination given pursuant to this Section 5.1 shall
effect termination as of the date specified in such notice or, in the event no
such date is specified, on the last day of the month in which such notice is
delivered or deemed delivered as provided in Section 9 below.

         5.2      The Company may terminate the Executive's employment at any
time without cause upon delivery of written notice to the Executive. Any notice
of termination given pursuant to this Section 5.2 shall effect termination as of
the date specified in such notice or, in the event no such date is specified, on
the last day of the month in which such notice is delivered or deemed delivered
as provided in Section 9 below. If such termination shall occur under this
Section 5.2, then, in lieu of all other remedies and as liquidated damages,
Executive shall be entitled to continuation of Base Salary and health benefits
for a period of six (6) months from said date of termination with such Base
Salary continuation to be at the rate set forth in Section 3.1 or, if greater,
at the rate of Executive's then current compensation in effect as of the date of
termination.

         5.3      The parties may mutually agree at any time to terminate this
Agreement upon such terms and conditions as may be agreed upon in writing.

         5.4      This Agreement shall terminate without notice upon the date of
Executive's death or the date when Executive becomes "completely disabled" as
that term is defined in Section 6.2

         5.5      Notwithstanding any provision to the contrary herein, unless
otherwise provided herein or unless otherwise provided by law, Executive may at
any time terminate his employment with the Company hereunder. In such event, the
Company shall not be liable to Executive for the payment of any amount other
than accrued Base Salary and other accrued benefits required by law, prorated to
the date of termination. Executive will not be entitled to severance pay, pay in
lieu of notice or any other such compensation.

6.       DEATH OR DISABILITY DURING TERM OF EMPLOYMENT.

         6.1      Upon termination of Executive's employment pursuant to Section
5.4, Executive or his estate or personal representative, as the case may be,
shall be entitled to receive Executive's Base Salary and benefits for a period
of one month following the date of death or the date when Executive becomes
completely disabled.

         6.2      The term "completely disabled" as used in this Agreement shall
mean the inability of Executive to perform the essential functions of his
position under this Agreement by reason of any incapacity, physical or mental,
which the Board of the Company, based upon medical advice or an opinion provided
by a licensed physician acceptable to the Board of the Company and approved by
the Executive, which approval shall not be unreasonably withheld, determines to
have incapacitated Executive from satisfactorily performing any or all essential
functions of his position for the Company during the foreseeable future. Based
upon such medical advice or opinion, the determination of the Board of the
Company shall be final and binding and the date such determination is made shall
be the date of such complete disability for purposes of this Agreement.

                                       3
<Page>

7.       CONFIDENTIAL INFORMATION; NONSOLICITATION.

         7.1      Executive recognizes that his employment with the Company will
involve contact with information of substantial value to the Company, which is
not old and generally known in the trade, and which gives the Company an
advantage over its competitors who do not know or use it, including but not
limited to, techniques, designs, drawings, processes, inventions, developments,
equipment, prototypes, sales and customer information, and business and
financial information relating to the business, products, practices and
techniques of the Company (hereinafter referred to as "Confidential
Information"). Executive will at all times regard and preserve as confidential
such Confidential Information obtained by Executive from whatever source and
will not, either during his employment with the Company or thereafter, publish
or disclose any part of such Confidential Information in any manner at any time,
or use the same except on behalf of the Company, without the prior written
consent of the Company. As a condition of this Agreement, Executive will sign
and return a copy of the Company's "Proprietary Information and Inventions
Agreement," attached as Exhibit A.

         7.2      While employed by the Company and for one (1) year thereafter,
the Executive agrees that in order to protect the Company's confidential and
proprietary information from unauthorized use, that Executive will not, either
directly or through others, solicit or attempt to solicit any employee,
consultant or independent contractor of the Company to terminate his or her
relationship with the Company in order to become an employee, consultant or
independent contractor to or for any other person or business entity; or the
business of any customer, vendor or distributor of the Company which, at the
time of termination or one (1) year immediately prior thereto, was listed on
Company's customer, vendor or distributor list.

8.       ASSIGNMENT AND BINDING EFFECT.

         8.1      This Agreement shall be binding upon and inure to the benefit
of Executive and Executive's heirs, executors, personal representatives,
assigns, administrators and legal representatives. Because of the unique and
personal nature of Executive's duties under this Agreement, neither this
Agreement nor any rights or obligations under this Agreement shall be assignable
by Executive. This Agreement shall be binding upon and inure to the benefit of
the Company and its successors, assigns and legal representatives.

9.       NOTICES.

         9.1      All notices or demands of any kind required or permitted to be
given by the Company or Executive under this Agreement shall be given in writing
and shall be personally delivered (and receipted for) or mailed by certified
mail, return receipt requested, postage prepaid, addressed as follows:

                  9.1.1             If to the Company:

                                    LARRY G. STAMBAUGH
                                    MAXIM PHARMACEUTICALS, INC.
                                    8899 UNIVERSITY CENTER LANE
                                    SUITE 400
                                    SAN DIEGO, CA  92122

                                       4
<Page>

                  9.1.2             If to Executive:

                                    KURT R. GEHLSEN, PH.D.
                                    MAXIM PHARMACEUTICALS, INC.
                                    8899 UNIVERSITY CENTER LANE
                                    SUITE 400
                                    SAN DIEGO, CA  92122

Any such written notice shall be deemed received when personally delivered or
three (3) days after its deposit in the United States mail as specified above.
Either Party may change its address for notices by giving notice to the other
Party in the manner specified in this section.

10.      CHOICE OF LAW.

         10.1     This Agreement is made in San Diego, California. This
Agreement shall be construed and interpreted in accordance with the laws of the
State of California.

11.      INTEGRATION.

         11.1     This Agreement contains the complete, final and exclusive
agreement of the Parties relating to the subject matter of this Agreement, and
supersedes all prior oral and written employment agreements or arrangements
between the Parties.

12.      AMENDMENT.

         12.1     This Agreement cannot be amended or modified except by a
written agreement signed by Executive and the Company.

13.      WAIVER.

         13.1     No term, covenant or condition of this Agreement or any breach
thereof shall be deemed waived, except with the written consent of the Party
against whom the wavier in claimed, and any waiver or any such term, covenant,
condition or breach shall not be deemed to be a waiver of any preceding or
succeeding breach of the same or any other term, covenant, condition or breach.

14.      SEVERABILITY.

         14.1     The finding by a court of competent jurisdiction of the
unenforceability, invalidity or illegality of any provision of this Agreement
shall not render any other provision of this Agreement unenforceable, invalid or
illegal. Such court shall have the authority to modify or replace the invalid or
unenforceable term or provision with a valid and enforceable term or provision
which most accurately represents the parties' intention with respect to the
invalid or unenforceable term or provision.

15.      INTERPRETATION; CONSTRUCTION.

         15.1     The headings set forth in this Agreement are for convenience
of reference only and shall not be used in interpreting this Agreement. This
Agreement has been drafted by legal counsel representing the Company, but
Executive has been encouraged, and has consulted with, his own independent
counsel and tax advisors with respect to the terms of this Agreement. The
Parties acknowledge that each Party and its counsel has reviewed and revised, or
had an opportunity to review and revise, this Agreement, and the normal rule of
construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of this Agreement.

                                       5
<Page>

16.      REPRESENTATIONS AND WARRANTIES.

         16.1     Executive represents and warrants that he is not restricted or
prohibited, contractually or otherwise, from entering into and performing each
of the terms and covenants contained in this Agreement, and that his execution
and performance of this Agreement will not violate or breach any other
agreements between Executive and any other person or entity.

17.      COUNTERPARTS.

         17.1     This Agreement may be executed in two counterparts, each of
which shall be deemed an original, all of which together shall contribute one
and the same instrument.

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first above written.

                                      The Company:

                                      MAXIM PHARMACEUTICALS, INC.

                                      By:   /s/ LARRY G. STAMBAUGH
                                      ------------------------------------------
                                      Larry G. Stambaugh
                                      Chairman of the Board, President and Chief
                                      Executive Officer

                                      EXECUTIVE:

                                      /s/ KURT R. GEHLSEN
                                      ------------------------------------------
                                      Kurt R. Gehlsen, Ph.D.

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]